Πέμπτη 29 Δεκεμβρίου 2016

Trastuzumab emtansine too expensive for routine funding on NHS, says NICE

Kadcyla (also called trastuzumab emtansine and made by Roche) is currently being funded in the UK for NHS use through the Cancer Drugs Fund. NICE is looking again at its 2015 guidance on the drug to see whether it should be funded routinely on the...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2itqiJk
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις